Vision-based Assessment of Joint Extensibility in Ehlers Danlos Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05366114 |
Recruitment Status :
Enrolling by invitation
First Posted : May 9, 2022
Last Update Posted : November 3, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Ehlers Danlos Syndrome (EDS) is a heterogenous group of genetic disorders with 13 identified subtypes. Hypermobile EDS (hEDS), although the most common subtype of EDS, does not yet have an identified genetic mutation for diagnostic confirmation. Generalized joint hypermobility (GJH) is one of the hallmark features of hEDS. The scoring system used in measurement of GJH was described by Beighton. The Beighton score is calculated using a dichotomous scoring system to assess the extensibility of nine joints. Each joint is scored as either hypermobile (score = 1) or not hypermobile (score = 0). The total score (Beighton score) can vary between a minimum of 0 and a maximum of 9, with higher scores indicating greater joint laxity.
While there is moderate validity and inter-rater variability in using the Beighton score, there continue to be several challenges with its widespread and consistent application by clinicians. Some of the barriers reported in the literature include:
i) In open, non-standardized systems there can be significant variation in the method to perform these joint extensibility tests including assessing baseline measurements, ii) Determining consistent and standard measurement tools/methodology e.g. goniometer use can vary widely iii) Assessing the reliability of the cut off values and, iv) Performing full assessment prior to informing patients of possible classification of GJH positivity (low specificity and low positive predictive).
Inappropriate implementation of tests to assess GJH results in inaccurate identification of GJH and potentially unintended negative consequences of making the wrong diagnosis of EDS. The objective of this study is to create a more robust and valid method of joint mobility measurement and reduce error in the screening of EDS through use of a smartphone-based machine learning application systems for measurement of joint extensibility.
The project will:
i) Create a smart-phone enabled visual imaging app to assess the measurement of joint extensibility, ii) Assess the feasibility of using the smart-phone app in a clinical setting to screen potential EDS patients, iii) Determine the validity of the application in comparison to in person clinical assessment in a tertiary care academic EDS program. If successful, the smart-phone application could help standardize the care of potential EDS patients in an efficient and cost-effective manner.
Condition or disease | Intervention/treatment |
---|---|
Ehlers-Danlos Syndrome | Other: No intervention, additional video data collection only |
Study Type : | Observational |
Estimated Enrollment : | 225 participants |
Observational Model: | Case-Only |
Time Perspective: | Cross-Sectional |
Official Title: | Assessing the Feasibility of a Smartphone-based, Machine Learning Visual Imaging Application for Assessment of Hyperextensibility of Peripheral Joints in Ehlers Danlos Syndrome |
Actual Study Start Date : | April 26, 2022 |
Estimated Primary Completion Date : | May 2023 |
Estimated Study Completion Date : | May 2023 |

Group/Cohort | Intervention/treatment |
---|---|
New patients at the GoodHope EDS clinic at Toronto General Hospital
All patients seen in the EDS clinic are eligible for inclusion, regardless of their presenting diagnosis or the results of their assessments.
|
Other: No intervention, additional video data collection only
No intervention will be used. Consenting participants will have video recordings taken during their exam of joint hypermobility which will be analyzed at a later time |
- Comparison of agreement in predicted angle by pose-estimation library [ Time Frame: 4 months ]The performance of the developed machine learning models for predicting the range of motion will be analyzed by the pose-estimation library used. This analysis will be performed on the subset of the data collected during the first 2 months of data collection. This information will be used to select the pose-estimation libraries to proceed with when refining the machine learning models.
- Comparison of agreement in predicted angle by joint [ Time Frame: 1 year ]The performance of the developed machine learning models for predicting the range of motion at each joint (spine, knee, ankle, elbow, shoulder, thumb, fifth finger) will be analyzed independently for each joint. This will provide insight with respect to which joints the system is more accurate at predicting from video.
- Assess the accuracy of range of motion prediction using vision-based data [ Time Frame: 1 year ]Machine learning models trained on videos of individuals performing the joint hypermobility maneuvers will be developed. Their performance will be compared to the range of motion measured by an expert clinician using a goniometer.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- All patients seen in the GoodHope EDS clinic at Toronto General are eligible for inclusion, regardless of their presenting diagnosis or the results of their assessments
Exclusion Criteria:
- Patients who do not consent to participate will not be included (participants may withdraw consent at any time)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05366114
Canada, Ontario | |
GoodHope EDS - Toronto General Hospital | |
Toronto, Ontario, Canada, M5G 2C4 |
Principal Investigator: | Nimish Mittal, MD | GoodHope Ehlers Danlos Syndrome Clinic, Toronto General Hospital |
Responsible Party: | Nimish Mittal, Medical Director - GoodHope Ehlers Danlos Syndrome Clinic, University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT05366114 |
Other Study ID Numbers: |
22-5073 |
First Posted: | May 9, 2022 Key Record Dates |
Last Update Posted: | November 3, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | No IPD will be shared with other researchers. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Ehlers-Danlos Syndrome Computer-vision Video |
Smartphone Beighton Score Joint Range of Motion |
Ehlers-Danlos Syndrome Syndrome Disease Pathologic Processes Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Hemorrhagic Disorders |
Hematologic Diseases Skin Abnormalities Congenital Abnormalities Skin Diseases, Genetic Genetic Diseases, Inborn Collagen Diseases Connective Tissue Diseases Skin Diseases |